	RM I		1449	9 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						File No. 99-16D3			Serial No. 10/787,442	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)									Applicant(s): Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond					
S. S	THE THAT THE THE THE THE THE THE THE THE THE TH										Filing Date: Group: 1647 February 26, 2004			
	U.S. PATENT DOCUMENTS EXAMINER DOCUMENT FILING DATE IF													
	IMINE TIAL	DOCUMENT NUMBER				DATE	Name		CLASS	SUBCLASS		FILING DATE IF APPROPRIATE		
	JS		ΑI		0/456,262		06-06-03	Nelson et al.			BUDGERS		ATTROTALE	
	ī		A2		1/285,970		11/23/05	Yee				=	 	
	1		A3		1/346,580	•	02-02-06	Novak et al.						
			A4		004-00091	50	01-15-04	Nelson et al.			1			
			A5	2	004-01109	32	06/10/04	Novak et al.				_		
	L		A6		005-00952		05-05-05	Sivakumar et al.						
			A7		005-02449		11/03/05	Presnell et al.						
			48.		005-02659		12-01-05	Kindsvogel et al	·					
<u> </u>	4_	_	A9		006-01347	54	06/22/06	Chan et al.	· · · · · · · · · · · · · · · · · · ·			=		
<u> </u>	4_	_	AIO		,307,024		10/23/01	Parrish et al. NO	ovak clal			_		
├	1		All	_	,605,272		08/12/03	Dillon et al.				-		
<u></u> *`	AY.		A12		,686,178		02-03-04	Dillon et al.						
 			A13	Ь	,929,932		08/16/05	Presnell et al.						
							FO	REIGN PATE	NT DOCUM	ENTS				
	Examiner		DOCUMENT			т				_			FILING DATE IF	
Ini	Initial JS		1	NUMBER 04/07285		-	Date COUNTRY			CLASS	SUBCLASS		APPROPRIATE	
-				A14 04/03285 A15 05/03730			04/22/04 WO 04/28/05 WO		 	-				
 	\		_	A15 05/03730 A16 99/61617			12/02/99 WO					_		
\vdash				A17 04/11270		_	12/29/04	wo				_		
	<u> </u>						<u> </u>	<u> </u>	has Title D	-4- Dortino	-t Potonto	-4- \		
<u> </u>		-	A18		JINEK.			(Including Aut						
	JS					Hill et al., "Cytokines: promoters and dampeners of au Biology LTD 14(6):791-797, 2002.				toimmunity," Current Opinion in Immunology, Current				
	·		A19		Clegg et al., "Therapeutic Opportunities for IL-21," European Cytokine Network vol. 14, no. Supplement 3, 2003.									
		L		_[
			A20			Nelson, et al., "Interleukin 21 has anti-tumor activity in animal models without the toxicity of IL-2," Procedures of the American Association for Cancer Research Annual Meeting, vol. 44, July 2003.								
	_	1		_j									•	
		<i>V</i>	A2I			Funa Publi	ro et al., "Moi ishing Barking	et al., "Monoclonal antibodies and therapy of human cancers," Biotechnology Advances, Elsevier ng Barking, GB vol. 18 no. 5, 2000.						
Ex	amir	ner	/Je	ga	theesa		eharasey		Date considered 01/03/2007					
thr		h cit						whether or not of considered.						

Ceve 10/30/